<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">32538885</PMID><DateCompleted><Year>2020</Year><Month>11</Month><Day>20</Day></DateCompleted><DateRevised><Year>2020</Year><Month>11</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1878-6448</ISSN><JournalIssue CitedMedium="Internet"><Volume>46</Volume><Issue>4</Issue><PubDate><Year>2020</Year></PubDate></JournalIssue><Title>NeuroRehabilitation</Title><ISOAbbreviation>NeuroRehabilitation</ISOAbbreviation></Journal><ArticleTitle>Is cell-based therapy more efficacious for people with amyotrophic lateral sclerosis/motor neuron disease than placebo or no treatment? - A Cochrane review summary with commentary.</ArticleTitle><Pagination><StartPage>613</StartPage><EndPage>615</EndPage><MedlinePgn>613-615</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/NRE-209004</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Even if there is sparse evidence of efficacy of stem cell administration for amyotrophic lateral sclerosis (ALS) in preclinical studies, the clinical use of cell-based therapy is yet to be defined.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To assess the efficacy, feasibility and safety of cell-based therapy in people with ALS/MND, compared with placebo or no treatment.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A Cochrane Review on the topic was summarized with comments.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Two randomized controlled trials met the selection criteria, but only one provided data useful for the analysis. It compared autologous bone marrow-mesenchymal stem cells, combined with riluzole, to riluzole only, in 64 people with ALS. The ALS Functional Rating Scale-Revised score slightly improved 6 months after the intervention, though the change was not clinically meaningful. Respiratory function, overall survival and the risk of total adverse events or serious adverse events were not different in the two groups.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The available evidence does not support the use of bone marrow-mesenchymal stem cells to treat people with ALS/MND.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ceravolo</LastName><ForeName>Maria Gabriella</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>Department of Experimental and Clinical Medicine, Politecnica delle Marche University, Ancona, Italy. E-mail: m.g.ceravolo@univpm.it.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>NeuroRehabilitation</MedlineTA><NlmUniqueID>9113791</NlmUniqueID><ISSNLinking>1053-8135</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045164" MajorTopicYN="N">Mesenchymal Stem Cell Transplantation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015990" MajorTopicYN="N">Placebo Effect</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALSFRS-R</Keyword><Keyword MajorTopicYN="N">Mesenchymal stem cells</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">functional recovery</Keyword><Keyword MajorTopicYN="N">respiratory function</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>6</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>11</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>6</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32538885</ArticleId><ArticleId IdType="doi">10.3233/NRE-209004</ArticleId><ArticleId IdType="pii">NRE209004</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>